This highly sensitive GLP-1 ELISA (enzyme-linked immunosorbent assay) kit is produced exclusively for the quantitative determination of bioactive glucagon like peptide-1 (7-36) [GLP-1 (7-36)] levels in human plasma. This kit is sensitive to 0.2 pmol/l, making it possible to establish baseline levels of GLP-1 (7-36).

Assay standards, controls, and test samples are added directly to the wells of a microplate that is coated with streptavidin. Subsequently, a mixture of biotinylated GLP-1 (7-36) specific antibody and a horseradish peroxidate (HRP) conjugated GLP-1 (7-36) specific antibody is added to each well. After the first incubation period, a sandwich immunocomplex of Streptavidin - Biotin-Antibody - GLP-1 (7-36) - HRP conjugated antibody forms attached to the walls of the plate. The unbound HRP conjugated antibody is removed in a subsequent washing step. For the detection of this immunocomplex, each well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to GLP-1 (7-36) on the walls of the microplate wells is directly proportional to the amount of GLP-1 (7-36) in the sample.

ALPCO Immunoassays was founded in 1990 as an importer and distributor of high quality research immunoassay kits. The company’s goals then, as now, have been to offer a diverse line of assays that appeal to their broad customer base while providing exceptional customer service and product support.
In recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and manufacturer of immunoassays in support of diabetes and obesity researchers as well. As the interest in animal models of insulin sensitivity in obese and pre-diabetic conditions continues to grow, ALPCO remains committed to serving the unique demands of this market with features including small sample volumes, reproducibility, robustness, and easy to follow protocols requiring minimal hands-on time.